Immunovant Inc. (IMVT)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement
Immunovant (IMVT) shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential best-in-class IgG reductions. I downgrade IMVT from "Strong Buy" to "Buy" due to competitive TED landscape and de-emphasis on batoclimab, despite robust upcoming catalysts. IMVT-1402 aims to address unmet needs in relapsed or uncontrolled GD patients, with pivotal data readouts expected in 2027 for additional indications like Myasthenia Gravis and difficult-to-treat rheumatoid arthritis.
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript
Immunovant, Inc. ( IMVT ) Q2 2026 Earnings Call November 10, 2025 8:00 AM EST Company Participants Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roivant Sciences Ltd.
Immunovant Inc. (IMVT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Immunovant Inc. ever had a stock split?
Immunovant Inc. Profile
| Biotechnology Industry | Healthcare Sector | Eric Venker CEO | NASDAQ (NGS) Exchange | 45258J102 CUSIP |
| US Country | 362 Employees | - Last Dividend | - Last Split | 21 Jun 2019 IPO Date |
Overview
Immunovant, Inc. is a forward-looking biopharmaceutical company engaged in the development of innovative treatments for autoimmune diseases. Positioned at the clinical stage, Immunovant focuses on pioneering monoclonal antibody therapies, a cutting-edge segment of medicinal treatment that harnesses the body's immune system to combat disease. Headquartered in New York, New York, Immunovant operates under the umbrella of its parent company, Roivant Sciences Ltd., indicating a strong backing and extensive resources for its research endeavors and potential market influence.
Products and Services
- Batoclimab
- Myasthenia Gravis: A chronic autoimmune neuromuscular disease that leads to varying degrees of skeletal muscle weakness.
- Thyroid Eye Disease: An autoimmune condition that affects the orbit around the eye, characterized by inflammation, swelling, and eventually fibrosis, leading to discomfort and vision problems.
- Chronic Inflammatory Demyelinating Polyneuropathy: A neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms.
- Graves Diseases: An autoimmune disorder that results in the overproduction of thyroid hormones (hyperthyroidism).
- Warm Autoimmune Hemolytic Anemia: A condition where the immune system destroys red blood cells, leading to anemia.
A standout in Immunovant's portfolio, batoclimab represents a significant advancement in the monoclonal antibody domain, primarily targeting the neonatal fragment crystallizable receptor (FcRn). This novel, fully human antibody is currently under development for multiple autoimmune conditions, demonstrating the company’s commitment to addressing a range of challenging diseases. The conditions targeted by batoclimab include:
Contact Information
